Compare Crispr Therapeutics AG (CRSP) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Procter & Gamble Co — how do they compare? Crispr Therapeutics AG trades at $50.53 (market cap $4.97B), while Procter & Gamble Co trades at $147.93 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 68.4× Crispr Therapeutics AG's market cap, and Procter & Gamble Co pays a 2.92% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PG | |
|---|---|---|
Market Cap | $4.97B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $167.18 |
52-Week Low | $44.34 | $138.10 |
Enterprise Value | $3.32B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Procter & Gamble (PG) trades at $147.43, down 0.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.42. Revenue for 2025 reached $84.28 billion, with a net income margin of 19.16%, while valuation ratios like P/E of 21.36 and P/S of 4.09 reflect a premium to peers. Recent news highlights PG's dividend reliability and supply chain improvements.
The outlook for PG is mixed, with strong fundamentals and a 53.85% analyst buy rating supporting upside to a $161.71 consensus target, but risks include premium valuation concerns and soft demand. Investment appeal lies in its stable cash flow and 69-year dividend growth streak, though near-term volatility may persist due to economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
